Modified technique for thermal radiofrequency ablation of Thoracic dorsal root ganglia under combined fluoroscopy and CT guidance: a randomized clinical trial

• Main Authors: Raafat M. Reyad, Hossam Z. Ghobrial, Ehab H. Shaker, Ehab M. Reyad, Mohammed H. Shaaban, Rania H. Hashem, Wael M. Darwish
• Format: Article
• Language: English
• Published: BMC 2019-12-01
• Series: BMC Anesthesiology
• Subjects: Thermal radiofrequency ablation; Intractable pain; Chest malignancies; Transforaminal approach; Dorsal root ganglia; Suprapedicular approach
• Online Access: https://doi.org/10.1186/s12871-019-0906-4

Abstract Background This study is comparing thermal radiofrequency ablation (TRFA) of the thoracic dorsal root ganglia (TDRG) guided by Xper CT and fluoroscopy with the standard fluoroscopy. Methods This randomized clinical trial included 78 patients suffering from chronic refractory pain due to chest malignancies randomly allocated into one of two groups according to guidance of TRFA of TDRG. In CT guided group (n = 40) TRFA was done under integrated Xper CT-scan and fluoroscopy guidance, while it was done under fluoroscopy guidance only in standard group (n = 38). The primary outcome was pain intensity measured by visual analog scale (VAS) score, functional improvement and consumption of analgesics. The secondary outcome measures were patient global impression of changes (PGIC) and adverse effects. Results VAS scores decreased in the two groups compared to baseline values (p < 0.001) and were lower in CT guided group up to 12 weeks. Pregabalin and oxycodone consumption was higher in the standard group at 1, 4 and 12 weeks (p < 0.001). Functional improvement showed near significant difference between the two groups (P = 0.06 at week 1, 0.07 at week 4 respectively) while the difference was statistically significant at week 12 (P = 0.04). PGIC showed near significant difference only at week 1 (P = 0.07) while the per-patient adverse events were lower in CT guided group (p = 0.027). Conclusions Integrated modality guidance with Xper CT-scan and fluoroscopy together with suprapedicular inferior transforaminal approach may improve efficacy and safety of TRFA of TDRG for the treatment of intractable chest pain in cancer patients. Trial registration The study was retrospectively registered at clinicaltrials.gov on 04/22/2018 (Registration No.: NCT03533413).